Investor Presentaiton

Immunology LPA₁1 Sotyktu CD19 NEX T Development in Sjögren's Syndrome supported by Phase 2 results in SLE 88 M Unmet Need SjS is an autoimmune disease characterized by dry eye and mouth with potential involvement of other organs No approved therapies that slow the progression of SjS Most patients require supportive care to manage symptoms¹ • . Disease mechanism and genetic data support reason to believe Genetic studies implicate TYK2 pathways in SjS² Interferon activity is increased systemically and in tissue of patients with SjS³ SjS and SLE have shared pathogenesis with common biomarkers and lab findings Based on similarity to SLE and high unmet need, the Phase 3 trial in Sjögren's Syndrome is ongoing 1. https://sjogrens.org/understanding-sjogrens/treatment; 2. Khatri B, et al. Nature Communications. 2022;13(4287):1-17. 3. Ill Bristol Myers Squibb Brkic Z, et al. Ann Rheum Dis. 2013;72:728-735. Not for Product Promotional Use 65

View entire presentation